Education
About Us
Working with TipRanks
Follow Us
Biomarin Pharmaceutical Inc. (BMRN)
NASDAQ:BMRN
BMRN Stock Chart & Stats
$57.62
$0.93(1.37%)
At close: 4:00 PM EST
$57.62
$0.93(1.37%)
Day’s Range― - ―
52-Week Range$50.76 - $73.51
Previous CloseN/A
Volume465.01K
Average Volume (3M)1.74M
Market Cap
$11.07B
Enterprise Value$10.42B
Total Cash (Recent Filing)$1.48B
Total Debt (Recent Filing)$611.19M
Price to Earnings (P/E)21.6
Beta0.46
Next Earnings
Feb 25, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding192,114,350
10 Day Avg. Volume1,855,903
30 Day Avg. Volume1,739,479
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.21
Price to Sales (P/S)4.38
P/FCF Ratio26.27
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.37
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda13.50
Forecast
1Y Price Target
$86.58Price Target Upside50.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactPending acquisition adds two FDA‑approved therapies, including an oral Fabry treatment, diversifying the product portfolio and expected to accelerate revenue growth by expanding commercial reach.
Clinical Development — DuchenneEarly trial results for BMN‑351 showed dose‑dependent increases in dystrophin, supporting continued development for Duchenne muscular dystrophy and the potential for a meaningful future commercial opportunity.
Pivotal Trial AdvancementEarly data for long‑acting BMN‑333 demonstrated clear dose‑related increases in free CNP and support initiating a pivotal registration trial with potential to improve treatment convenience through weekly dosing.
Bears Say
Asset Write-downs And EarningsA material Roctavian‑related asset write‑down will reduce reported non‑GAAP earnings and create a near‑term profit headwind for the company.
Financial Leverage And DilutionFinancing the acquisition largely with new non‑convertible debt increases financial leverage, raises execution risk, and could make the deal slightly dilutive to earnings in 2026 due to higher interest costs.
Intellectual Property RiskIntellectual property uncertainty around Voxzogo creates an overhang that could limit upside and constrain market access until legal issues are resolved.
BioMarin Pharmaceutical News
BMRN FAQ
What was Biomarin Pharmaceutical Inc.’s price range in the past 12 months?
Biomarin Pharmaceutical Inc. lowest stock price was $50.76 and its highest was $73.51 in the past 12 months.
What is Biomarin Pharmaceutical Inc.’s market cap?
Biomarin Pharmaceutical Inc.’s market cap is $11.07B.
When is Biomarin Pharmaceutical Inc.’s upcoming earnings report date?
Biomarin Pharmaceutical Inc.’s upcoming earnings report date is Feb 25, 2026 which is in 19 days.
How were Biomarin Pharmaceutical Inc.’s earnings last quarter?
Biomarin Pharmaceutical Inc. released its earnings results on Oct 27, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.12.
Is Biomarin Pharmaceutical Inc. overvalued?
According to Wall Street analysts Biomarin Pharmaceutical Inc.’s price is currently Undervalued.
Does Biomarin Pharmaceutical Inc. pay dividends?
Biomarin Pharmaceutical Inc. does not currently pay dividends.
What is Biomarin Pharmaceutical Inc.’s EPS estimate?
Biomarin Pharmaceutical Inc.’s EPS estimate is 0.71.
How many shares outstanding does Biomarin Pharmaceutical Inc. have?
Biomarin Pharmaceutical Inc. has 192,114,350 shares outstanding.
What happened to Biomarin Pharmaceutical Inc.’s price movement after its last earnings report?
Biomarin Pharmaceutical Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 1.557%.
Which hedge fund is a major shareholder of Biomarin Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in BMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$86.58 (50.26% Upside)
$86.58 (50.26% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.35%
12-Months-Change
Fundamentals
Return on Equity
9.07%
Trailing 12-Months
Asset Growth
11.15%
Trailing 12-Months
Company Description
Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted BioMarin's strong revenue growth, particularly with VOXZOGO and enzyme therapies, alongside a solid cash position and operational efficiency. However, challenges included a significant IPR&D charge, the decision to divest ROCTAVIAN, and enzyme therapy revenue fluctuations. While there are notable achievements, the presence of significant lowlights balances the overall sentiment.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$86.58
▲(50.26% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―
Ownership Overview
0.44% Insiders
30.55% Mutual Funds
0.86% Other Institutional Investors
47.33% Public Companies and Individual Investors